Most head and neck cancer patients were still on opioids months after radiation

Design

Single-institution retrospective cohort with multivariable analysis

Population

789 patients with non-metastatic head and neck cancer given definitive radiation or chemoradiation

Primary outcome

Opioid use 3 months after completing radiation

Effect

70% at 3 months, 47% at 6 months; predictors prior opioid use (2.57), former smoking (1.55), palliative referral (3.90)

Head and neck cancer and its treatment cause severe, prolonged pain, which makes this group vulnerable to long-term opioid use. This single-institution cohort of 789 patients treated with definitive radiation or chemoradiation tracked opioid use afterwards.

Nearly all — 95% — were prescribed opioids at some point, and use persisted: 70% were still taking them three months after radiation and 47% at six months. Among those opioid-naive before treatment, 58% were still on opioids at three months. Continued use at three months was more likely with prior opioid use, former smoking, or a palliative-care referral; in naive patients, being underweight strongly predicted earlier opioid start.

The message for ENT and oncology teams is that acute pain control quietly becomes long-term use in this group, and no one owns the taper. A structured stewardship plan — anticipating the high-risk patient, setting a review point, and planning de-escalation as mucositis heals — is warranted alongside, not instead of, adequate analgesia during treatment.

• 70% of patients were still taking opioids 3 months after radiation and 47% at 6 months (95% were prescribed them at some point).
• Continued use at 3 months was predicted by prior opioid use (adjusted odds ratio 2.57), former smoking (1.55) and palliative-care referral (3.90).
• Among opioid-naive patients, 58% were still on opioids at 3 months; underweight status strongly predicted earlier start.
• Set a review and taper plan for high-risk patients as mucositis heals, rather than leaving long-term use unmanaged.

Why it matters

It shows acute cancer-pain prescribing turning into persistent use with no one responsible for stopping it.

Don't overread it

Single-institution and observational — it identifies risk factors and a high prevalence, not that any specific stewardship programme reduces dependence.

The statistics, in plain English

That 70% remained on opioids at three months is a crude but striking proportion; the adjusted odds ratios identify who is most at risk, though as a single-centre study the exact figures may not transfer directly to other populations.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.